TUMOR NECROSIS FACTOR INHIBITORS

Course overview

TUMOR NECROSIS FACTOR (TNF)-ALPHA INHIBITORS, INCLUDING ETANERCEPT (E), INFLIXIMAB (I), ADALIMUMAB (A), CERTOLIZUMAB PEGOL (C), AND GOLIMUMAB (G), ARE BIOLOGIC AGENTS WHICH ARE FDA-APPROVED TO TREAT ANKYLOSING SPONDYLITIS (E, I, A, C, AND G), CROHN DISEASE (I, A AND C), HIDRADENITIS SUPPURATIVA (A), JUVENILE IDIOPATHIC ARTHRITIS (A), PLAQUE PSORIASIS (E, I AND A), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (E), PSORIATIC ARTHRITIS (E, I, A, C, AND G), RHEUMATOID ARTHRITIS (E, I, A, C, AND G), ULCERATIVE COLITIS (I, A AND G), AND UVEITIS (A). THERE ARE ALSO SEVERAL OFF-LABEL INDICATIONS. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM OF ACTION, METHODS OF ADMINISTRATION, IMPORTANT ADVERSE EFFECTS, CONTRAINDICATIONS, TOXICITY, AND MONITORING, OF TUMOR NECROSIS FACTORS, SO PROVIDERS CAN DIRECT PATIENT THERAPY WHERE THEY ARE INDICATED AS PART OF THE INTERPROFESSIONAL TEAM.